Impact of empagliflozin on left atrial mechanical and conduction functions in patients with type 2 diabetes mellitus
[ X ]
Tarih
2023
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wiley
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Objective Empagliflozin, an oral anti-diabetic drug that inhibits the sodium-dependent glucose co-transporter 2 (SGLT2), has pleiotropic effects on the myocardium. The aim of the study is to investigate the effect of empagliflozin on atrial electromechanical delay (AEMD) and the left atrial (LA) mechanical functions in patients with type 2 diabetes mellitus (DM). Method In total 62 patients (40.3% female, mean age 50.5 +/- 8.6 years old) with type 2 DM were enrolled to the study. Participants were used a SGLT2 inhibitor (empagliflozin 10-25 mg/daily) for 6 months. Patients were examined initially and after 6 months with echocardiography. LA volume was recorded, atrial conduction times were measured using tissue Doppler imaging (TDI). Results No significant change was observed in LA volumes (maximal, minimal, and presystolic), total emptying and passive emptying volume at the end of 6 months; however, there was a significant decrease in active emptying volume (8.3 +/- 2.9 ml/m(2) vs. 7.9 +/- 2.9 ml/m(2), p = 0.04). The posteroanterior lateral, septal, and tricuspid conduction times significantly decreased after the empagliflozin treatment. The decrease in right inter-AEMD was statistically significant (13.25 +/- 10.21 ms vs. 10.85 +/- 9.14 ms, p = 0.011). The changes in inter-AEMD were found to be correlated with the changes in LA active emptying volume (r = 0.408). Conclusion Empagliflozin may enhance the structure and electrical conductions of the atrium and may prevent DM patients from DM-2-related functional disorder and arrhythmia.
Açıklama
Anahtar Kelimeler
atrial electromechanical delay, diabetes mellitus, empagliflozin, tissue Doppler echocardiography
Kaynak
Journal of Clinical Ultrasound
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
51
Sayı
3
